# FDA Approves Blood Test for Alzheimer's Detection in Adults Over 55
The FDA has cleared a new blood test designed to detect early signs of Alzheimer's disease in people aged 55 and older. The test measures phosphorylated tau, a protein that accumulates in the brains of Alzheimer's patients years before cognitive symptoms appear.
This approval marks a shift toward earlier disease detection. Previously, confirming Alzheimer's required either PET imaging of the brain or cerebrospinal fluid analysis via spinal tap. Both methods were expensive, invasive, and difficult to access outside specialized medical centers. A blood test changes the equation entirely.
The new test works by identifying p-tau217 or p-tau181, versions of tau protein modified by phosphorylation. Research published over the past five years, particularly studies from Washington University School of Medicine and Swedish researchers, demonstrated these biomarkers appear in blood 10 to 20 years before memory loss begins. This window offers a genuine opportunity for intervention before irreversible brain damage accumulates.
The practical advantage is real. Blood tests cost far less than imaging, take minutes rather than hours, and work in any clinical setting. Primary care physicians can order the test during routine visits. Patients avoid radiation exposure from PET scans or the risks associated with lumbar puncture. This accessibility matters especially for underserved populations who rarely access specialists.
But the test has real limitations. A positive result does not mean someone has Alzheimer's disease. It indicates the presence of pathology. Brain imaging studies show that 30 percent of cognitively normal older adults have amyloid or tau accumulation without symptoms. Some of these individuals will never develop dementia.
The test also cannot predict who will progress or how quickly decline will occur. A positive blood biomarker is a risk indicator, not a diagnosis. The FDA approval specifically notes this distinction in its labeling. Patients need follow-up evaluation including cognitive testing, neuroimaging, and clinical assessment.
Another constraint involves age. The test shows strongest predictive value in people with cognitive complaints or family history of Alzheimer's. Screening asymptomatic adults without risk factors may generate false positives and unnecessary anxiety. Major medical organizations, including the Alzheimer's Association, recommend the test primarily for people with memory concerns or those pursuing research studies.
Insurance coverage remains uncertain. Some plans may balk at funding a screening test on asymptomatic patients, particularly given that no approved disease-modifying treatments exist for earliest stages. Lecanemab (Leqembi), recently approved by the FDA, shows modest slowing of cognitive decline in people with mild cognitive impairment caused by Alzheimer's pathology. But it requires amyloid PET confirmation and carries risks including amyloid-related imaging abnormalities (ARIA), which can cause brain microhemorrhages or microinfarcts.
The blood test represents genuine progress in early detection. It removes barriers to identifying pathology early. But it functions as a screening tool, not a diagnostic test, and cannot replace clinical judgment. People with positive results need comprehensive evaluation by memory specialists to understand what the result means for their individual situation and whether treatment is appropriate.